Clinical Trial Update: Intratumoral Injections of LL37 for Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 clinical trial evaluating intratumoral injections of LL37 for melanoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• LL37

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-12-09